Skip to main content

Advertisement

Table 2 HBcAb positive “only” patients characteristics

From: Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma

   Rituximab containing protocols  
Variable Overall Yes No p
No. of patients 96 48 48 ns
Age - Mean [±SD] 64,39 ± 9,63 65,17 ± 10,21 64,02 ± 8,37 ns
Sex – M/F M: 57 M: 30 M: 27 ns
F: 39 F: 18 F: 21
Lymphoma type Indolent: 50 Indolent: 17 Indolent: 33 0,001
Aggressive: 46 Aggressive: 31 Aggressive: 15
Probable OBI reactivation 10 [10,42%] 5 [10,42%] 5 [10,42%] ns
NUC profilaxys/rescue therapy 0/10 0/5 0/5 ns
“Per year Incidence of reactivation” [mean ± SD] 8,23% ± 9,84 9,08% ± 10,69 11,54% ± 40,74 ns
Reactivation time [mean weeks after therapy] 26,67 ± 12,20 31,60 ± 14,50 20,50 ± 4,72 ns
Liver related decompensations/hospitalizations/deaths 0% 0% 0% -
  1. No statistical differences were found in patients treated with ad without Rituximab. (Chi-square, Pearson corrected calculations for all variables, Age, incidence of reactivation and reactviation time: student t-test).